Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. [electronic resource]
Producer: 20170127Description: 935-940 p. digitalISSN:- 0392-856X
- Adalimumab -- economics
- Biological Products -- adverse effects
- Certolizumab Pegol -- economics
- Cost-Benefit Analysis
- Drug Costs
- Etanercept -- economics
- Humans
- Models, Economic
- Randomized Controlled Trials as Topic
- Recovery of Function
- Remission Induction
- Sacroiliac Joint -- diagnostic imaging
- Spine -- diagnostic imaging
- Spondylarthritis -- diagnostic imaging
- Time Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.